8-K filed Jun 15, 2026 at 16:07 ET
On June 13 and June 15, 2026, Rhythm Pharmaceuticals released positive interim clinical data from its Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS) and multiple data presentations across acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS), and PWS at ENDO 2026. Six-month PWS data showed a -3.06% mean BMI reduction, preservation of lean mass, and clinically meaningful hyperphagia improvements, with 8 of 10 moderate-to-severe patients achieving a ≥7-point HQ-CT reduction. Additional data showed -18.9% mean BMI reduction at 2.5 years in HO with setmelanotide, encouraging 1-year oral bivamelagon data in HO, and real-world BBS outcomes. The company confirmed plans to advance into Phase 3 trials for PWS, reinforcing the MC4R agonism thesis and expanding the addressable market opportunity.